• Molecular NameDextroamphetamine
  • Synonym(+)-(s)-amphetamine; (+)-alpha-methylphenethylamine; (+)-alpha-methylphenylethylamine; (+)-amphetamine; (+)-phenaminum; (2S)-(+)-Amphetamine; (2S)-1-phenylpropan-2-amine; (s)-(+)-amphetamine; (s)-(+)-beta-phenylisopropylamine; (S)-1-phenyl-2-aminopropane; (S)-1-Phenyl-2-propanamine; (S)-1-phenyl-2-propylamine; (s)-alpha-methylbenzeneethanamine; (s)-alpha-methylphenethylamine; (s)-alpha-phenylethylamine; (s)-amphetamine; 1-Methyl-2-phenylethylamine; D-(+)-amphetamine; D-(s)-amphetamine; D-1-Phenyl-2-aminopropan; d-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; D-alpha-methylphenethylamine; D-am; D-amphetamine; Desamfetamina; Dexamfetamina [inn-spanish]; Dexamfetamine; Dexamfetaminum [inn-latin]; Dexamphetamine; Dexamphetaminum [inn-latin]; Dexanfetamina [inn-spanish]; Dextroamphetamine; Dextroamphetamine sulfate; S(+)-amphetamine
  • Weight135.21
  • Drugbank_IDDB01576
  • ACS_NO1462-73-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.82
  • pkaN/A
  • LogD (pH=7, predicted)-0.87
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.87
  • LogSw (predicted, AB/LogsW2.0)1.86
  • Sw (mg/ml) (predicted, ACD/Labs)5.42
  • No.of HBond Donors2
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds2
  • TPSA26.02
  • StatusFDA approved
  • AdministrationOral, Intravenous, Sublingual, Vaporized, Insufflated, Rectal
  • PharmacologyA psychostimulant drug which is known to produce increased wakefulness and focus in association with decreased fatigue and decreased appetite.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability75.0
  • Protein binding24.5
  • Volume of distribution (VD)6.11 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe main metabolic pathway is dextroamphetamine \rightarrow \; phenylacetone \rightarrow \; benzoic acid \rightarrow \; hippuric acid. Another pathway, mediated by enzyme CYP2D6, is dextroamphetamine \rightarrow \; p-hydroxyamphetamine \rightarrow \; p-hydroxynorephedrine. Although p-hydroxyamphetamine is a minor metabolite (~5% of the dose), it may have significant physiological effects as a norepinephrine analogue.
  • Half life12 h
  • ExcretionRenal: ~45%
  • Urinary Excretion14.5
  • Clerance3.4~7.7 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A